TY - JOUR
T1 - Meningococcal ACWY conjugate vaccine immunogenicity and safety in adolescents with juvenile idiopathic arthritis and inflammatory bowel disease
T2 - A prospective observational cohort study
AU - Ohm, Milou
AU - van Straalen, Joeri W
AU - Zijlstra, Marieke
AU - de Joode-Smink, Gerrie
AU - Jasmijn Sellies, Anne
AU - Swart, Joost F
AU - Vastert, Sebastiaan J
AU - van Montfrans, Joris M
AU - Bartels, Marije
AU - van Royen-Kerkhof, Annet
AU - Wildenbeest, Joanne G
AU - Lindemans, Caroline A
AU - Wolters, Victorien
AU - Wennink, Roos A W
AU - de Boer, Joke H
AU - Knol, Mirjam J
AU - Heijstek, Marloes W
AU - Sanders, Elisabeth A M
AU - Verduyn-Lunel, Frans M
AU - Berbers, Guy A M
AU - Wulffraat, Nico M
AU - Jansen, Marc H A
N1 - Funding Information:
We thank all adolescents who participated in the study. Furthermore, we thank Debbie van Rooijen for her help with laboratory measurements.
Publisher Copyright:
© 2023
PY - 2023/6/7
Y1 - 2023/6/7
N2 - Background: Immunogenicity to meningococcal serogroup ACWY (MenACWY) conjugate vaccine has not been studied in immunocompromised minors with juvenile idiopathic arthritis (JIA) or inflammatory bowel disease (IBD). We determined immunogenicity of a MenACWY-TT vaccine in JIA and IBD patients at adolescent age and compared results to data from aged-matched healthy controls (HCs). Methods: We performed a prospective observational cohort study in JIA and IBD patients (14–18 years old), who received a MenACWY vaccination during a nationwide catch-up campaign (2018–2019) in the Netherlands. Primary aim was to compare MenACWY polysaccharide-specific serum IgG geometric mean concentrations (GMCs) in patients with HCs and secondary between patients with or without anti-TNF therapy. GMCs were determined before and 3–6, 12, and 24 months postvaccination and compared with data from HCs at baseline and 12 months postvaccination. Serum bactericidal antibody (SBA) titers were determined in a subset of patients at 12 months postvaccination. Results: We included 226 JIA and IBD patients (66 % and 34 % respectively). GMCs were lower for MenA and MenW (GMC ratio 0·24 [0·17-0·34] and 0·16 [0·10-0·26] respectively, p < 0·01) in patients compared to HCs at 12 months postvaccination. Anti-TNF users had lower MenACWY GMCs postvaccination compared with those without anti-TNF (p < 0·01). The proportion protected (SBA ≥ 8) for MenW was reduced in anti-TNF users (76 % versus 92 % in non-anti-TNF and 100 % in HCs, p < 0.01). Conclusion: The MenACWY conjugate vaccine was immunogenic in the vast majority of JIA and IBD patients at adolescent age, but seroprotection was lower in patients using anti-TNF agents. Therefore, an extra booster MenACWY vaccination should be considered.
AB - Background: Immunogenicity to meningococcal serogroup ACWY (MenACWY) conjugate vaccine has not been studied in immunocompromised minors with juvenile idiopathic arthritis (JIA) or inflammatory bowel disease (IBD). We determined immunogenicity of a MenACWY-TT vaccine in JIA and IBD patients at adolescent age and compared results to data from aged-matched healthy controls (HCs). Methods: We performed a prospective observational cohort study in JIA and IBD patients (14–18 years old), who received a MenACWY vaccination during a nationwide catch-up campaign (2018–2019) in the Netherlands. Primary aim was to compare MenACWY polysaccharide-specific serum IgG geometric mean concentrations (GMCs) in patients with HCs and secondary between patients with or without anti-TNF therapy. GMCs were determined before and 3–6, 12, and 24 months postvaccination and compared with data from HCs at baseline and 12 months postvaccination. Serum bactericidal antibody (SBA) titers were determined in a subset of patients at 12 months postvaccination. Results: We included 226 JIA and IBD patients (66 % and 34 % respectively). GMCs were lower for MenA and MenW (GMC ratio 0·24 [0·17-0·34] and 0·16 [0·10-0·26] respectively, p < 0·01) in patients compared to HCs at 12 months postvaccination. Anti-TNF users had lower MenACWY GMCs postvaccination compared with those without anti-TNF (p < 0·01). The proportion protected (SBA ≥ 8) for MenW was reduced in anti-TNF users (76 % versus 92 % in non-anti-TNF and 100 % in HCs, p < 0.01). Conclusion: The MenACWY conjugate vaccine was immunogenic in the vast majority of JIA and IBD patients at adolescent age, but seroprotection was lower in patients using anti-TNF agents. Therefore, an extra booster MenACWY vaccination should be considered.
KW - Adolescents
KW - Anti-TNF agents
KW - Biologicals
KW - Immunocompromised
KW - Immunogenicity
KW - Inflammatory bowel disease
KW - Juvenile idiopathic arthritis
KW - MenACWY vaccination
KW - Safety
UR - http://www.scopus.com/inward/record.url?scp=85159338659&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2023.04.056
DO - 10.1016/j.vaccine.2023.04.056
M3 - Article
C2 - 37198018
SN - 0264-410X
VL - 41
SP - 3782
EP - 3789
JO - Vaccine
JF - Vaccine
IS - 25
ER -